ENOB HV 21
Alternative Names: Adaptive allogenic cell therapy - Renovaro Biosciences; Allogenic natural killer and gamma delta T-cell therapy; Allogenic NK and GD-T Cell therapy; ENOB-HV-21; KIR/HLA mismatched allogenic NK and gamma-delta T cell therapy; NK-GDT therapy; RENB-HV-21Latest Information Update: 21 Aug 2023
At a glance
- Originator Enochian BioSciences
- Developer Renovaro Biosciences; Seraph Research Institute
- Class NKT cell therapies; T lymphocyte cell therapies
- Mechanism of Action Natural killer cell replacements; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended HIV infections